”Orum has granted Vertex rights to conduct research using its TPD² approach to developing degrader-antibody conjugates (DACs), next-generation versions of antibody-drug conjugates (ADCs) which use antibodies to precisely deliver small molecule targeted protein degrader payloads to cancer cells and other targeted biological therapies.”
a new platform for ADC development….n... - Advanced Prostate...
a new platform for ADC development….no sorry, it’s DAC this time! not PCa related but hopefully soon
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
very interesting article on DAC’s as it’s still early phase
Not what you're looking for?
You may also like...
new approach: not PCa related but maybe in the future
counter intuitive but very interesting (reminds me of BAT somehow) will be tested on humans soon it...
Chemo or clinical trial?
Am scheduled for bone biopsy of met(s) from my hip tomorrow. Stopped Pluvicto after #3 due to...
PSA going down, but ALP increasing
I'm 3 weeks into a clinical trial for ARV-766, an AR degrader. At 2 weeks, my PSA had dropped from...
Hyperthermia: I do not talk often about this but it’s a good approach
well, at 46 C degrees human cells die…I think that the best part of such treatment would be that...
New to this, but have followed for a year
Thank all of you for the things I have learned and the inspiration over the last year. I was...
Related Posts
Starting clinical trial of AVR-766
Lutetium-177 PSMA - A new experimental treatment
Tomotherapy side effects?
Long term AR signaling‐targeted therapy with taxane sometimes associated with visceral metastasis in castration‐resistant prostate cancer
PSMA-targeted radiopharmaceutical clinical trials in the US
